India Fast Emerging as Global Powerhouse in Pharma & MedTech R&D

According to Lok Sabha Speaker Om Birla, India is quickly establishing itself as a global hub for pharmaceuticals and medical research. In New Delhi, Birla said this at the 7th International Conference of the Innovative Physicians Forum (IPF Medicon 2025).

Birla referenced India’s healthy ecosystem in the healthcare sector, and India has become a leader in drug manufacturing, vaccine production and biomedical innovation.

He indicated that Indian doctors, scientists and medical professionals gained worldwide recognition during the COVID-19 pandemic as they demonstrated excellence and innovation in healthcare through constraints and limited resources. In addition to New Delhi promoting a qualitatively, accessible and affordable healthcare infrastructure in India, the country is also seeing unprecedented levels of foreign investment coming into the country.

 The pharma and medical device sectors lured over Rs 11,888 crore in Foreign Direct Investments (FDI) between the period of April to December 2024, in addition to Rs 7,246 crore through brownfield investments—both demonstrating the level of confidence from the global economy in the Indian life sciences ecosystem.

Also Read: How to Bridge the Healthcare Gap in Emerging Markets with MedTech

The government’s flagship health programs like Ayushman Bharat and the National Digital Health Mission are remoting reformations to equitable access through research initiatives. As such, Birla clarified that the Indian healthcare and pharmaceuticals will have a transformative role in the global economy with continued R&D, the development of qualified human capital and policy solicitation.

With rising exports, expanding infrastructure, and global partnerships, India is fast becoming a preferred destination for pharmaceutical innovation and medical research excellence.